We predict that activation of TREM2 through the use of antibodies like AL002a will prove to be a novel, innovative therapeutic approach to the treatment of AD that will lack the adverse events observed with direct binding of Aβ in the brain by anti-Aβ antibodies. The gene discussed is TREM2; the disease is Alzheimer disease.